Now that another year has passed it is great to see the NanoString Digital Spatial profiling microscope near its commercial launch. The platform will be in early access to select customers in the fourth quarter of 2018, and full commercial launch in the first half of 2019. For those interested […]
John Iafrede (Massachusetts General Hospital, MA) “There is a tidal wave of cell-free approaches; little performance testing; and the big question is who is going to pay for it.” This year’s Assocation for Molecular Pathology was held in Salt Lake City, Utah from November 15-18, 2017. (You can find the […]
While at the Association for Molecular Pathology in Salt Lake City Utah, I was able to interview Gang Song CEO of Pillar Biosciences to ask him about the challenges in the clinical laboratory that Pillar is tackling, about the basics of SLIMamp technology, and recent news. Check it out! #AMP2017
With over 2000 clinical laboratory professionals in molecular diagnostics and pathology, plenty of technology and offerings on display. This year the Association for Molecular Pathology takes place in Salt Lake City Utah, and promises an abundance of new technology as well as the new accompanying science around diagnostic testing. Since […]
Executive “TL;DR” Summary: An interesting platform called SlipChip with potential point-of-care applications, for fast and potentially very inexpensive digital PCR Update: This work has been recently published (Oct 2017) in Science Translational Medicine. While at the recent Next Generation Diagnostics Summit (organized by the Cambridge Healthtech Institute and held in […]
“Amateurs focus on identifying their weakness and improving them. Professionals focus on their strengths and on finding people who are strong where they are weak.” Shane Parrish, Farnham Street Blog I am happy to announce today that I have joined Pillar Biosciences in Natick MA. (For those not familiar with […]
“Keep working no matter what happens If things are good, keep working. If things are bad, keep working.” Moby (American singer-songwriter) I am happy to say that my stint of being in-between employers has come to an end. (Details will be forthcoming.) I’d like to say now (in that period […]
What happens when commercial interests do not align? Over a decade ago in 2002 when Novartis announced it was moving its global headquarters to Boston MA, it was viewed at the time that the United State’s pharmaceutical market was the most robust and attractive, and it made sense for Novartis […]
A ‘gold rush’ multi-billion dollar business, three targets, four cancer drugs, four antibody-based companion diagnostic tests, sixteen FDA approvals The human immune system is remarkable. When you think about the preponderance of death by infectious disease throughout history, the top two causes of death in 1900 was influenza and pneumonia, […]
This post is about Seracare’s new direction for Precision Medicine (in particular Precision Oncology), and the launch of a new product the Seraseq Solid Tumor Mutation Mix-I (AF20). But I’ll start first with a story from my days at Illumina. It was ten years ago this week that I last […]
One way the world of work has changed with the advent of social media has been the immediacy and intimacy of information. Immediate, as the ability to push ‘tweet’ or ‘publish’ sends your message or blog post out into the vast reaches of electronic communication; and intimate, as social media […]
Congratulations are in order to the US Food and Drug Administration for approving the Illumina MiSeqDx™ system, including two Cystic Fibrosis assays, and two additional approvals for the platform (the instrument and the reagents). This is the first next-generation sequencer approved by the FDA, an important milestone reflecting a sea-change […]
